Cadrenal Therapeutics, Inc.
CVKDNasdaqCIK 1937993HealthcareFiscal year ends Dec 31
Reports and events: 91 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0713:23 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-107442 |
| 2026-09-2920:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-104647 |
| 2026-08-3112:29 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-095394 |
| 2026-08-1320:31 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001213900-26-089153 |
| 2026-08-1320:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-089147 |
| 2026-08-0321:09 ET | DEF 14A | Proxy statementPeriod 2026-09-24 | 0001213900-26-084710 |
| 2026-07-2112:30 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-079824 |
| 2026-07-1720:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-079176 |
| 2026-07-1020:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-077134 |
| 2026-07-0121:23 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-074421 |
| 2026-06-2921:19 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-073213 |
| 2026-06-1813:02 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-069902 |
| 2026-06-0320:25 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-064744 |
| 2026-05-0712:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-053075 |
| 2026-05-0712:30 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001213900-26-053074 |
| 2026-04-3012:40 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-049754 |
| 2026-04-0111:40 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits | 0001213900-26-038014 |
| 2026-03-3113:02 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001213900-26-036946 |
| 2026-03-3112:55 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-036937 |
| 2026-03-1212:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-026646 |
| 2026-02-2413:35 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-019606 |
| 2025-12-2902:27 ET | S-1 | Registration statement | 0001213900-25-125526 |
| 2025-12-2321:58 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-125433 |
| 2025-12-1613:24 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-25-121932 |
| 2025-12-1113:17 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-120360 |
| 2025-12-0114:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-116307 |
| 2025-11-1821:23 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-112123 |
| 2025-11-1014:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-25-107949 |
| 2025-11-1011:21 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001213900-25-107816 |
| 2025-09-2420:05 ET | 8-K | 5.07 Shareholder vote results | 0001213900-25-091109 |
| 2025-09-1513:53 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-087461 |
| 2025-08-1120:52 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-25-074355 |
| 2025-08-1110:09 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001213900-25-073885 |
| 2025-08-0513:12 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-071764 |
| 2025-07-3110:43 ET | DEF 14A | Proxy statementPeriod 2025-09-24 | 0001213900-25-069612 |
| 2025-07-1820:49 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.08 Item not in the standard list; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-065710 |
| 2025-05-0820:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-25-041049 |
| 2025-05-0810:17 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001213900-25-040788 |
| 2025-04-1710:12 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-032732 |
| 2025-03-1321:17 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-25-023762 |
| 2025-03-1321:15 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001213900-25-023759 |
| 2025-03-0413:05 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-019747 |
| 2025-02-0721:09 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-011315 |
| 2025-01-2900:29 ET | SCHEDULE 13D | Ownership report, active investor | 0001213900-25-007997 |
| 2024-11-0721:01 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001213900-24-095393 |
| 2024-11-0714:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-24-095195 |
| 2024-11-0421:41 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-094155 |
| 2024-10-2413:10 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-090153 |
| 2024-09-2520:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-081799 |
| 2024-09-0520:59 ET | 8-K | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001213900-24-076144 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.